Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin

Antiemesis

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan

(2015) Kazuo Tamura et al.   International Journal of Clinical Oncology

Prevention of Delayed Nausea: A University of Rochester Cancer Center Community Clinical Oncology Program Study of Patients Receiving Chemotherapy

(2012) Joseph A. Roscoe et al.   JOURNAL OF CLINICAL ONCOLOGY

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

(2010) F. Roila et al.   ANNALS OF ONCOLOGY

Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin

(2010) Toshiaki Takahashi et al.   CANCER SCIENCE

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

(2009) Bernardo L. Rapoport et al.   SUPPORTIVE CARE IN CANCER